All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2008-007762-39 | A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Rilonacept for the Prophylaxis of Gout Flares During the Initiation of Allopurinol Therapy | 2011-02-09 | due-trials |
| Reported results | 2008-007784-16 | A Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial of the Safety of Rilonacept for the Prophylaxis of Gout Flares in Patients on Urate Lowering Therapy. | 2011-02-16 | due-trials |
| Reported results | 2008-008200-40 | A Double-Masked, Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema (DME) | 2010-09-07 | due-trials |
| Reported results | 2011-003836-29 | A randomized, double-blind, placebo-controlled, repeat-dose study of the efficacy, safety, tolerability, and pharmacodynamics of subcutaneously-administered REGN668 in adult patients with extrinsic mo... | 2013-06-25 | due-trials |
| Reported results | 2011-004308-39 | A Phase 2 Pilot Study with a Randomized Double-Blind Treatment Phase to Evaluate the Pharmacodynamics and Safety of REGN727 in Patients with Autosomal Dominant Hypercholesterolemia and Gain-of-Functio... | 2017-07-28 | due-trials |
| Reported results | 2012-000946-37 | A randomized, double-blind, parallel-group, placebo-controlled study to assess the safety of REGN668 administered concomitantly with topical corticosteroids to patients with moderate-to-severe Atopic ... | 2012-12-20 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2012-001221-27 | A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients with Primary Hypercholesterolemia Who are Intolerant to Statins... | 2017-05-29 | bad-data |
| Reported results | 2012-001222-95 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients with Heterozygous Familial Hypercholesterolemia Not Adequately... | 2015-01-09 | due-trials |
| Reported results | 2012-002333-11 | A Randomized, Double-Blind Study of the Efficacy and Safety of REGN727 Added-on to Rosuvastatin versus Ezetimibe Added-on to Rosuvastatin versus Rosuvastatin Dose Increase in Patients Who are Not Cont... | 2014-06-06 | due-trials |
| Reported results | 2012-002344-24 | A Randomized, Double-Blind Study of the Efficacy and Safety of REGN727 Added-on to Atorvastatin versus Ezetimibe Added-on to Atorvastatin versus Atorvastatin Dose Increase versus Switch to Rosuvastati... | 2014-05-06 | due-trials |
| Reported results | 2012-003651-11 | A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study investigating the efficacy, safety, pharmacokinetic and biomarker profiles of Dupilumab (REGN668) administered to adu... | 2014-09-10 | due-trials |
| Reported results | 2013-001449-15 | AN OPEN-LABEL STUDY OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS DUPILUMAB CLINICAL TRIALS | 2022-06-27 | due-trials |
| Reported results | 2013-002343-29 | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients with Primary Hypercholesterolemia | 2015-04-28 | due-trials |
| Completed, but no date, and reported results | 2013-003134-33 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF 3-MONTH SUBCUTANEOUS REGN1033 TREATMENT IN PATIENTS WITH SARCOPENIA | bad-data | |
| Reported results | 2013-003254-24 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONG-TERM SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | 2016-10-19 | due-trials |
| Reported results | 2014-001198-15 | A PHASE 3 CONFIRMATORY STUDY INVESTIGATING THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY ADMINISTERED TO ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | 2016-02-12 | due-trials |
| Completed, but no date, and reported results | 2014-001917-20 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia Undergoing Lipid Aphe... | bad-data | |
| Reported results | 2014-002619-40 | A PHASE 3 CONFIRMATORY STUDY INVESTIGATING THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY ADMINISTERED TO ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | 2016-01-21 | due-trials |
| Trial is partly outside EEC, and reported results | 2014-003263-37 | A Phase 2A Study Investigating the Safety, Pharmacokinetics, Immunogenicity, and Exploratory Efficacy of Dupilumab in Patients Aged ≥6 to <18 Years With Atopic Dermatitis | 2016-03-14 | bad-data |
| Reported results | 2014-003384-38 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE EFFICACY AND SAFETY OF MULTIPLE DUPILUMAB DOSE REGIMENS ADMINISTERED AS MONOTHERAPY FOR MAINTAINING TREATMENT RESPONSE I... | 2016-11-18 | due-trials |
| Other | 2015-001396-40 | An open-label extension study to assess the long-term safety and efficacy of dupilumab in patients ≥6 months to <18 years of age with atopic dermatitis | not-yet-due | |
| Exempt | 2015-001697-17 | A Phase 1 Study to Assess Safety and Tolerability of REGN1979, an anti-CD20 x anti- CD3 bispecific monoclonal antibody, and REGN2810, an anti-programmed death-1 (PD-1) monoclonal antibody, in Patients... | not-yet-due | |
| Reported results | 2015-001714-96 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Pre... | 2017-09-26 | due-trials |
| Reported results | 2015-002653-35 | A phase 3 study investigating the efficacy, safety, and tolerability of Dupilumab administered to adult patients with severe atopic dermatitis who are not adequately controlled with or are intolerant ... | 2017-03-30 | due-trials |
| Reported results | 2015-003782-28 | A RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH MODERATE TO SEVERE CHRONIC LOW BACK PAIN | 2017-09-26 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-003783-36 | A Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Long-Term Safety and the Efficacy of Fasinumab in Patients with Pain Due to Osteoarthritis of the Knee or Hip | 2021-08-31 | bad-data |
| Trial is outside EEC, and reported results | 2015-004458-16 | Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2016-000105-36 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH – 1 (PD-1), IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA | 2023-10-18 | bad-data |
| Completed, but no date, and reported results | 2016-000411-32 | AN OPEN-LABEL, SINGLE-ARM, PROOF-OF-CONCEPT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SINGLE AND MULTIPLE DOSES OF REGN1500 IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2016-000955-28 | A phase 2/3 study investigating the pharmacokinetics, safety, and efficacy of Dupilumab in patients aged ≥6 months to <6 years with moderate-to- severe atopic dermatitis | 2021-07-08 | bad-data |
| Reported results | 2016-002639-14 | A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients with Moderately Severe to Severe Nonproliferative Diabetic Retinopathy | 2019-07-16 | due-trials |
| Reported results | 2016-003122-16 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1, IN PATIENTS WITH ADVANCED BASAL CELL CARCINOMA WHO EXPERIENCED PROGRESSION OF DISEASE ON HEDGEHOG PATHWAY INHIBITO... | 2023-04-27 | due-trials |
| Reported results | 2016-003189-16 | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients with Heterozygous Familial Hypercholesterolemia or with Non-Familial Hype... | 2020-03-10 | due-trials |
| Reported results | 2016-003307-62 | A Phase 2, Randomized, Placebo-Controlled Study of Safety and Efficacy, Following Repeat-Dose Administration of Evinacumab (anti-ANGPTL3) in Patients with Severe Hypertriglyceridemia (sHTG) at Risk fo... | 2020-07-23 | due-trials |
| Ongoing | 2016-004407-31 | A GLOBAL, RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF REGN2810 (ANTI-PD 1 ANTIBODY) VERSUS PLATINUM BASED CHEMOTHERAPY IN FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC PD L1 + NON-SMALL CE... | not-yet-due | |
| Reported results | 2016-004997-16 | A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of dupilumab administered concomitantly with topical corticosteroids in patients ≥6 years to <12 years of ag... | 2019-09-09 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-005020-29 | A Phase 3 Randomized, Double-blind, Multi-dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients with Pain Due to Osteoarthritis of the Knee or Hip | 2021-08-27 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2016-005035-33 | A randomized, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and effects on heterotopic bone formation of REGN2477 in patients with Fibrodysplasia Ossificans Progressiv... | 2021-09-16 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-000350-19 | An open-label, randomized, phase 3 clinical trial of REGN2810 versus investigator's choice of chemotherapy in recurrent or metastatic cervical carcinoma | 2023-04-20 | bad-data |
| Reported results | 2017-000351-95 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALIROCUMAB IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | 2020-02-13 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-001041-27 | A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Platinum based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in... | 2021-07-29 | bad-data |
| Ongoing | 2017-001311-36 | A Randomized, Phase 3, Open-label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2017-001388-19 | A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia | 2020-03-17 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-001508-31 | A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients with Persistent Hypercholesterolemia Despite Maximally Tole... | 2020-12-14 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-001702-15 | A Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo And NSAID-Controlled Study To Evaluate The Efficacy And Safety Of Fasinumab In Patients With Pain Due To Osteoarthritis Of The Knee Or Hip | 2020-11-09 | bad-data |
| Reported results Terminated | 2017-001943-12 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients with Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip o... | 2019-05-03 | due-trials |
| Other | 2017-002139-41 | An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an anti CD20 x anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2017-003170-13 | An open-label study to evaluate the long-term safety and efficacy of evinacumab in patients with homozygous familial hypercholesterolemia STUDIO IN APERTO PER VALUTARE LA SICUREZZA E L’EFFICACIA A... | 2023-04-13 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-003684-35 | A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (Cemiplimab; Anti-PD-1 Antibody) and Ipilimumab (Anti CTLA 4 Antibody) in the Second-Line Treatment of Patients with A... | 2021-10-27 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-004921-33 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients with Pain Due to Osteoarthritis of the Hip or Knee | 2021-01-07 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-000844-25 | A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Eosinophilic Esophagitis (EoE) | 2022-06-07 | bad-data |
| Completed, but no date, and reported results Terminated | 2018-001411-71 | Study to Evaluate Synovial Fluid in the Phase 3 Fasinumab Program for Osteoarthritis of the Knee and Hip | bad-data | |
| Reported results | 2018-001543-30 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2A STUDY TO ASSESS THE EFFICACY AND SAFETY OF REGN3500 MONOTHERAPY AND COMBINATION OF REGN3500 PLUS DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-S... | 2020-07-28 | due-trials |
| Reported results | 2018-001544-64 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY INVESTIGATING THE EFFICACY, SAFETY, AND PHARMACOKINETIC PROFILES OF REGN3500 ADMINISTERED TO ADULT PATIENTS... | 2020-07-24 | due-trials |
| Reported results Terminated | 2018-001618-13 | Study to Evaluate Arthroplasty Specimens in the Phase 3 Fasinumab Program for Osteoarthritis of the Knee and Hip | 2020-10-27 | due-trials |
| Reported results | 2018-002477-22 | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY IN CAT-ALLERGIC PATIENTS WITH ASTHMA TO EVALUATE THE EFFICACY OF A SINGLE DOSE OF REGN1908-1909 TO REDUCE BRONCHOCONSTRICT... | 2020-04-06 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2018-002734-20 | An Open Label, Single Arm Study to Evaluate the Efficacy and Safety of REGN3918 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Are Complement Inhibitor Naive or Have Not Recently Recei... | 2021-06-10 | bad-data |
| Reported results | 2018-002810-11 | Long Term Safety Study of PRALUENT in Patients with Heterozygous Familial Hypercholesterolemia or with Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk and Previously Enroll... | 2020-04-08 | due-trials |
| Exempt | 2018-003188-78 | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | not-yet-due | |
| Reported results Terminated | 2018-004730-15 | A Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of REGN5069 in Patients with Pain due to Osteoarthritis of the Knee | 2020-10-29 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2019-000130-20 | An open-label extension study to evaluate the long-term safety, tolerability, and efficacy of REGN3918 in patients with paroxysmal nocturnal hemoglobinuria | 2022-04-07 | bad-data |
| Other | 2019-000566-38 | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2019-001764-29 | Randomized, Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients with Retinopathy of Prematurity | 2022-08-18 | bad-data |
| Exempt | 2019-001908-38 | A PHASE 1/2 STUDY OF REGN5093 IN PATIENTS WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER Étude de phase I/II portant sur REGN5093 chez des patients atteints d'un cancer du poumon non à petite... | not-yet-due | |
| Reported results | 2019-001931-30 | A Three-Part, Single-Arm, Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Evinacumab in Pediatric Patients with Homozygous Familial Hypercholesterolemia | 2023-05-30 | due-trials |
| Listed as ongoing, but also has a completion date | 2019-002619-24 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients with Allergic Bronchopulmonary Aspergillosis | 2024-02-09 | bad-data |
| Other | 2019-002742-20 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Patients with Moderate-to-Severe Asthma | not-yet-due | |
| Other | 2019-003007-35 | A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC) | not-yet-due | |
| Trial is outside EEC | 2019-003078-24 | A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis | bad-data | |
| Reported results | 2019-003088-22 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Moderate-to-Severe Atopic Hand... | 2022-11-23 | due-trials |
| Exempt | 2019-003298-24 | A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Recurrent Ovarian Cancer Estudio en fase I/II de REGN4018 (un a... | not-yet-due | |
| Other | 2019-003520-20 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2019-003643-30 | A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients with Diabetic Macular Edema | 2024-06-18 | bad-data |
| Completed, but no date | 2020-001239-29 | A PHASE 2 STUDY OF CEMIPLIMAB, AN ANTI-PD-1 MONOCLONAL ANTIBODY, AND ISA101B VACCINE IN PATIENTS WITH RECURRENT/METASTATIC HPV16 CERVICAL CANCER WHO HAVE EXPERIENCED DISEASE PROGRESSION AFTER FIRST LI... | bad-data | |
| Exempt | 2020-002031-29 | A PHASE 1/2 STUDY OF REGN7257 (ANTI-INTERLEUKIN 2 RECEPTOR SUBUNIT GAMMA [IL2RG] MONOCLONAL ANTIBODY) IN PATIENTS WITH SEVERE APLASTIC ANEMIA THAT IS REFRACTORY TO OR RELAPSED ON IMMUNOSUPPRESSIVE THE... | not-yet-due | |
| Exempt, with results | 2020-002537-15 | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS CoV 2 Monoclonal Antibodies for the Treatment of Hospitalized Patients with COVID-19 | 2021-10-22 | not-yet-due |
| Completed, reported early | 2020-002761-33 | A RANDOMIZED, OPEN-LABEL ECULIZUMAB AND RAVULIZUMAB CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBI... | 2023-12-07 | not-yet-due |
| Ongoing | 2020-003272-41 | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients with Symptomatic Generalized Myasthenia Gravis | not-yet-due | |
| Reported results | 2020-003654-71 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-Cov-2 Infection in Household Contacts ... | 2021-10-04 | due-trials |
| Exempt, with results | 2020-003690-21 | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS CoV 2 Monoclonal Antibodies for the Treatment of Ambulatory Patients with COVID-19 | not-yet-due | |
| Completed, reported early | 2020-004094-52 | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy of Anti-Bet v 1 Monoclonal Antibodies to Reduce Symptoms of Seasonal Allergic Rhinitis | 2024-08-23 | not-yet-due |
| Ongoing | 2020-004486-40 | A RANDOMIZED, OPEN-LABEL, C5 INHIBITOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE... | not-yet-due | |
| Completed, reported early | 2020-005005-17 | A Randomized, Open-label, Two-arm Study to Evaluate the Safety, Efficacy, and Pharmacodynamic Effects of Pozelimab and Cemdisiran Combination Treatment in Patients with Paroxysmal Nocturnal Hemoglobin... | 2023-10-18 | not-yet-due |
| Other | 2020-005875-10 | An Extension Study to Evaluate the Long-Term Outcomes of Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study | not-yet-due | |
| Completed, but no date | 2021-000138-33 | A Randomized Double-Blind Placebo-Controlled Study of the LEPR Agonist Antibody REGN4461 for the Treatment of Metabolic Abnormalities in Patients with Familial Partial Lipodystrophy Estudio aleator... | bad-data | |
| Reported results Terminated | 2021-000437-13 | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Evinacumab in Patients with Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis | 2023-02-15 | due-trials |
| Reported results | 2021-002089-42 | A Randomized, Double-Blind, Placebo-Controlled Study in Cat-Allergic Patients with Allergic Rhinitis Who Live with a Cat to Assess the Efficacy and Safety of Anti-Fel d 1 Antibodies during Natural Cat... | 2023-04-24 | due-trials |
| Other | 2021-004453-23 | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | not-yet-due | |
| Trial is outside EEC, and reported results | 2021-004535-84 | A Phase 1b, Open-Label, Single Dose Study Assessing the Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for ... | bad-data | |
| Trial is outside EEC, and reported results | 2021-004590-30 | A Phase 2a, Open-Label Study Assessing Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Single-Dose Subcutaneous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab and Imdevimab)... | bad-data | |
| Ongoing | 2021-004931-10 | An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria | not-yet-due | |
| Completed, but no date | 2021-006337-19 | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of REGN5381, an NPR1 Agonist, ... | bad-data | |
| Other | 2022-000880-40 | PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY AND EFFICACY OF GARETOSMAB IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA STUDIO DI FASE III RANDOMIZZATO, CONTRO... | not-yet-due | |
| Trial is outside EEC, and reported results | 2023-000604-19 | A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 i... | bad-data |